Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large‐cell lymphoma treated with brentuximab vedotin: A case series.

This article discusses the use of brentuximab vedotin (BV) for the treatment of relapsed or refractory anaplastic large-cell lymphoma (ALCL) in pediatric patients. The study focuses on the role of minimal residual disease (MRD) monitoring using droplet digital PCR (dPCR) to assess treatment response and predict relapse. The results suggest that multiple cycles of BV are necessary to achieve complete remission, and MRD positivity may serve as an early indicator of relapse. The study acknowledges its limitations due to its retrospective nature and small sample size. The research was supported by various funding sources and the authors declare no conflicts of interest. [Extracted from the article]